Table 3.
Comparison of clinical characteristics and effects of antitoxin therapies on live vs. dead TSS cases.
| Dead (n = 4) | Survivor (n = 26) | P | |
|---|---|---|---|
| Etiology of toxic shock syndrome | p = 0.5977 | ||
| - Sta-TSSa (%)b | 1 (7%) | 14 (93%) | |
| - Str-TSSc (%) | 3 (20%) | 12 (80%) | |
| Number of organ dysfunctions (SDd) | 5 (0, 8) | 4 (1, 3) | p = 0.04* |
| ARDSe (%) | 4/4 (100%) | 4/26 (15%) | p = 0.04* |
| PELODf score at D+1 (SD) | 28 (13, 7) | 12 (7, 1) | p = 0.04* |
| Antitoxin therapies (overall) | p = 0.04* | ||
| - No treatment (%) | 2 (67%) | 1 (33%) | |
| - At least one antitoxin therapies (clindamycin; clindamycin + IVIGg) (%) | 2 (7%) | 25 (93%) | |
| Antitoxin therapy: clindamycin only | p = 0.0813 | ||
| - No treatment (%) | 2 (67%) | 1 (33%) | |
| - Clindamycin only (%) | 1 (8%) | 11 (92%) | |
| Antitoxin therapy: clindamycin + IVIG | p = 0.5977 | ||
| - No treatment (%) | 3 (20%) | 12 (80%) | |
| - Clindamycin + IVIG (%) | 1 (7%) | 14 (93%) | |
| Antitoxin therapy: clindamycin + IVIG | p = 1.0000 | ||
| - Clindamycin only (%) | 1 (8%) | 11 (92%) | |
| - Clindamycin + IVIG (%) | 1 (7%) | 14 (93%) |
a
Sta-TSS, Staphylococcal Toxic Shock Syndrome.
b
%, percent of total population.
c
Str-TSS, Streptococcal Toxic Shock Syndrome.
d
SD, standard deviation.
e
ARDS, Acute Respiratory Distress Syndrome.
f
PELOD, Pediatric Logistic Organs Dysfunctions score.
g
IVIG, Intravenous Immunoglobulin.
*
Statistically significant data with the corresponding statistical test.